New biomarkers in heart failure

Progress in Pediatric Cardiology

Volumn 31, Issue 1, 2011, Pages 49-52

  Pincott, E Siân ^a   Burch, M ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Pediatric heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CHROMOGRANIN A; ESTROGEN DERIVATIVE; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR; NATRIURETIC FACTOR; OSTEOPROTEGERIN; ST2 PROTEIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RISK ASSESSMENT;

EID: 79451469884     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2010.11.009     Document Type: Article

References (31)

1. Cowie M.R., Wood D.A., Coates A.J.S., et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000, 83:505-510.
2. Wood D.A. Preventing clinical heart failure: rationale and scientific evidence. Heart 2002, 88:15-22.
3. Andrews R.E., Fenton M., Ridout D., Burch M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation 2008, 117:79-84. On behalf of the British Congenital Cardiac Association.
4. Iwanaga Y., Miyazaki S. Heart failure, chronic kidney disease, and biomarkers. Circulation Journal 2010, 74(7):1274-1282.
5. Chan D., Ng L.L. Biomarkers in acute myocardial infarction. BMC Med 2010, 8:34.
6. Howlett J.G., McKelvie R.S., Arnold J.M.O., et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 2009, 25(2):85-105.
7. Mueller T., Gegenhuber A., Dieplinger B., Poelz W., Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal pro-BNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004, 42:942-944.
8. Masson S., Latini R., Arnand I.S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal pro-BNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
9. Omland T., Sabatine M.S., Jablonski K.A., et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007, 50:205-214.
10. Mangat J., Carter C., Riley G., Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail 2009, 11(1):48-52.
11. Price J.F., Thomas A.K., Grenier M., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation Sep 5 2006, 114(10):1063-1069. [Epub 2006 Aug 28].
12. Auerbach S.R., Richmond M.E., Lamour J.M., et al. BNP levels predict outcome in pediatric heart failure patients: post-hoc analysis of the pediatric carvedilol trial. Circ Heart Fail 2010, 3:606-611.
13. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
14. Jougasaki M., Wei C.M., McKinley L.J., Burnett J.C. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92:286-289.
15. Maisel A. Biomarkers in the assessment of congestive heart failure: a multinational trial examining acute shortness of breath, heart failure, and a novel panel of biomarkers. Presented at the European Society of Cardiology - Munich 2009.
16. Shah R.V., James L., Januzzi James L. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010, 7:9-14.
17. Bartunek J., Delrue L., van Durme F., et al. Non-myocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol December 16 2008, 52(25):2166-2174.
18. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N.J., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
19. Kempf T., Eden M., Strelau J., et al. The transforming growth factor-β superfamily member growth differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006, 98:351-360.
20. Eggers K.M., Kempf T., Allhoff T., Lindahl B., Wallentin L., Wollert K.C. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 2008, 29:2327-2335.
21. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1054-1060.
22. Kempf T., Sinning J., Quint A., et al. Growth differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease. Circ Cardiovasc Genet 2009, 2:286-292.
23. Lok D.J.A. Relationship between galectin-3 and NTpro-BNP and outcome in patients with chronic congestive heart failure. ESC congress 2007 presentation 2007.
24. Lok D.J.A., van de Meer P., Bruggink-André de la Porte P.W., et al. Clin Res Cardiol 2010, 99:323-328.
25. Van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3 and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
26. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
27. Omland T., Drazner M.H., Uehland T., et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007, 49:1392-1398.
28. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553.
29. Ceconi C., Ferrari R., Bachetti T., et al. Chromogranin A in heart failure. A novel neurohumoral factor in predictor for mortality. Eur Heart J 2002, 23:967-974.
30. Wollert K.C., Drexler H. Chromogranin A in heart failure. Eur Heart J 2002, 23:926-927.
31. Jankowska E.A., Rozentryt P., Ponikowska B., et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA 2009, 301(18):1892-1901.